Elucidation of a new mechanisms of action on drug-drug interaction of

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K16435
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: Tokyo University of Pharmacy and Life Science (2022-2023); Hoshi University (2019-2021)
• Principal Investigator: Kenichi Suzuki 東京薬科大学, 薬学部, 教授 (40775508)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: 免疫チェックポイント阻害薬 / チロシンキナーゼ阻害薬 / 薬剤性肺障害

Outline of Final Research Achievements

This study experienced significant delays from the original plan due to the impact of the COVID-19 pandemic. As a result, no outcomes have yet been achieved that could lead to presentations at academic conferences. However, since 2023, we have established a collaborative research framework with the Department of Clinical Pharmacology at our university, the Pharmacy Department of Tokyo Medical University Hospital, and physicians specializing in thyroid surgery. We are making rapid preparations to start the research this year. We have agreed on the regimen and blood sampling schedule for the target lung cancer area. As of June 2024, we have completed the preparation of reagents and consumables for cytokine measurements, including IL-6, and we are currently preparing to apply for the IRB at Tokyo Medical University Hospital.

Free Research Field

がん化学療法　支持療法

Academic Significance and Societal Importance of the Research Achievements

昨今はICIとの同時併用レジメンが多く導入されており、併用による副作用増強の懸念がある。本研究の学術的意義としてICIと同時併用される薬剤への副作用増強などに対する注意喚起や投与量調整などの指針作成につながる可能性がある。また、EGFR-TKIの多くはCYP3Aの基質薬であり薬剤性肺障害を起こす薬剤である。発症した際の死亡率は約30-40％であり重篤度が高い。本研究の仮説はICI後の CYP3A基質薬の血中濃度やAUCが高まることに直結するものであり、2016年にPMDAから注意喚起された肺障害の機序の解明につながる可能性がある。